Available data also suggest that, similarly to what observed for IL-6R/IL-1R blockade [80,81] and systemic corticosteroid treatment [82], a TLR4-blocking therapeutic may critically prevent hyperinflammation in the lung and thereby ALI if administered at a later time point when exaggerated immune-mediated inflammation prevails. This evidence concerns the gene IL1R1 and acute respiratory distress syndrome.